Bempedoic acid Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Vendor-neutral scientific reference catalog

Adenosine triphosphate-citrate lyase (ACL) inhibitor; lipid-modifying agent compound Reference needs_revision Best effort · source review pending

Also known as: ETC-1002, ESP55016, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, Nexletol

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Storage

For the approved bempedoic-acid tablet formulation, labeling specifies storage in the original package at 20–25 °C. Storage conditions for neat research-grade bempedoic acid were not established from the authoritative sources reviewed.

Solubility

Highly soluble in ethanol, isopropanol, and pH 8 phosphate buffer; insoluble in water and in aqueous solutions below pH 5.

Best-Effort Research Profile

Bempedoic acid is a prodrug that requires CoA activation, primarily in the liver, to form the active metabolite ETC-1002-CoA. The active metabolite inhibits adenosine triphosphate-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol-biosynthesis pathway, thereby reducing hepatic cholesterol synthesis and LDL-C levels. It is an alpha,omega-dicarboxylic acid with a hydroxy substituent and four methyl substituents.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Mean steady-state human half-life: 21 ± 11 hours.

Onset

Pharmacokinetic steady state is achieved after approximately 7 days of repeated once-daily administration. LDL-C efficacy endpoints in labeling and clinical studies are commonly assessed at approximately 12 weeks; a distinct clinical onset time is not established in the cited authoritative sources.

Administration Routes (Research)

oral

Reported Research Effects

Inhibits ATP-citrate lyase after intracellular CoA activation.
Reduces hepatic cholesterol synthesis and lowers LDL-C, non-HDL-C, apolipoprotein B, and total cholesterol.
Has lipid-lowering activity through a mechanism upstream of HMG-CoA reductase.

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Reference information is based primarily on official U.S. and European regulatory labeling and PubChem records. The 180 mg strength and once-daily oral regimen refer to approved tablet formulations and are included as neutral reference information, not individualized dosing guidance. Raw-compound catalog sizes and storage conditions were not treated as verified scientific facts.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN: 738606-46-7; PubChem CID: 10472693; molecular formula: C19H36O5; molecular weight: 344.5 g/mol; IUPAC name: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; InChIKey: HYHMLYSLQUKXKP-UHFFFAOYSA-N; FDA UNII: 1EJ6Z6Q368; ATC: C10AX

Source-Backed Observations

Approved product labeling describes bempedoic acid as a white to off-white crystalline powder. The approved oral tablet contains 180 mg of bempedoic acid. Bempedoic acid and its active metabolite are highly plasma-protein bound. The active metabolite is ESP15228.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Bempedoic Acid, PubChem Compound Summary, CID 10472693
https://pubchem.ncbi.nlm.nih.gov/compound/Bempedoic-acid (accessed 2026-09-07)

NEXLETOL (bempedoic acid) U.S. Prescribing Information
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d06d89-a3da-40b4-b273-8f4f7d56c4c9 (accessed 2026-09-07)

Nilemdo: European Public Assessment Report overview
https://www.ema.europa.eu/en/medicines/human/EPAR/nilemdo (accessed 2026-09-07)

NEXLETOL (bempedoic acid) FDA label
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211616s022s023lbl.pdf (accessed 2026-09-07)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.